The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.

Interactions between the cyclin-dependent kinase inhibitor flavopiridol and the small-molecule Bcl-2 antagonist HA14-1 were examined in human multiple myeloma cells. Whereas individual treatment of U266 myeloma cells with 10 micromol/L HA14-1 or 100 nmol/L flavopiridol had little effect, exposure of cells to flavopiridol (6 hours) followed by HA14-1 (18 hours) resulted in a striking increase in mitochondrial dysfunction (cytochrome c and Smac/DIABLO release; loss of mitochondrial membrane potential), activation of the caspase cascade, apoptosis, and diminished clonogenic survival. Similar findings were noted in other myeloma cell lines (e.g., MM.1S, RPMI8226, and NCI-H929) as well as in those resistant to dexamethasone and cytotoxic agents (e.g., MM.1R, 8226/Dox40, and 8226/LR5). Combined exposure to flavopiridol and HA14-1 was associated with down-regulation of Mcl-1 and Bcl-xL, Bid cleavage, and mitochondrial translocation of Bax. Flavopiridol/HA14-1-treated cells also exhibited a pronounced activation of Jun NH2-terminal kinase, a modest activation of p38 mitogen-activated protein kinase, and down-regulation of cyclin D1. Flavopiridol/HA14-1-induced apoptosis was associated with a marked increase in reactive oxygen species generation; moreover,both events were attenuated by the antioxidant N-acetyl-l-cysteine. Finally, in contrast to dexamethasone, flavopiridol/HA14-1-induced lethality was unaffected by exogenous interleukin-6 or insulin-like growth factor-I. Together, these findings indicate that flavopiridol and the small-molecule Bcl-2 antagonist HA14-1 cooperate to trigger oxidant injury, mitochondrial dysfunction, caspase activation, and apoptosis in human multiple myeloma cells and suggest that this approach may warrant further evaluation as an antimyeloma strategy.

[1]  U. Maurer,et al.  High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[3]  C. Beam,et al.  Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. , 2003, Cancer research.

[4]  E. Anaissie,et al.  Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma , 2004, Clinical Cancer Research.

[5]  Kazuhito Yamamoto,et al.  BCL-2 Is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway Normally Activated at G2/M , 1999, Molecular and Cellular Biology.

[6]  D. Voehringer,et al.  Bcl-2 expression causes redistribution of glutathione to the nucleus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Tan,et al.  HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death , 2003, Leukemia.

[8]  R. Müller,et al.  Bcl-2 Independence of Flavopiridol-induced Apoptosis , 2000, The Journal of Biological Chemistry.

[9]  Y. Hsu,et al.  Conformation of the Bax C‐terminus regulates subcellular location and cell death , 1999, The EMBO journal.

[10]  P. Dent,et al.  Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. , 2001, Cancer research.

[11]  H. Pehamberger,et al.  Chemosensitisation of malignant melanoma by BCL2 antisense therapy , 2000, The Lancet.

[12]  B. Cheson,et al.  Clinical trials referral resource. , 1990, Oncology.

[13]  N. Munshi,et al.  Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. , 2002, Blood.

[14]  R. Schimke,et al.  BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. , 1995, Cancer research.

[15]  S. Corey,et al.  Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. , 2002, Leukemia research.

[16]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Grant,et al.  The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway , 2001, Cell Death and Differentiation.

[18]  J. Fay,et al.  Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody. , 1989, Cancer research.

[19]  L. Mileshkin,et al.  Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. , 2003, Blood.

[20]  P. Bergsagel,et al.  Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma , 2003, Immunological reviews.

[21]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[22]  B. Dörken,et al.  The IL‐6 receptor antagonist SANT‐7 overcomes bone marrow stromal cell–mediated drug resistance of multiple myeloma cells , 2001, International journal of cancer.

[23]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[24]  Yi-Te Hsu,et al.  Movement of Bax from the Cytosol to Mitochondria during Apoptosis , 1997, The Journal of cell biology.

[25]  N. Schor,et al.  Role of caspase 3-dependent Bcl-2 cleavage in potentiation of apoptosis by Bcl-2. , 2002, Molecular pharmacology.

[26]  S. Korsmeyer,et al.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c , 2000, Cell Death and Differentiation.

[27]  G. Morgan,et al.  Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells* , 2003, The Journal of Biological Chemistry.

[28]  D. Alberts,et al.  Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. , 1986, Cancer research.

[29]  I. Gojo,et al.  The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  D. Weiner,et al.  A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. , 1992, Blood.

[31]  S. Grant,et al.  The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells , 2003, Leukemia.

[32]  I. Gojo,et al.  Myeloid cell factor-1 is a critical survival factor for multiple myeloma. , 2002, Blood.

[33]  A. Lowell,et al.  Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. , 2003, Cancer research.

[34]  D. Price,et al.  Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo * , 2001, The Journal of Biological Chemistry.

[35]  M. Konopleva,et al.  Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. , 2002, Blood.

[36]  P. Dent,et al.  Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. , 2002, Blood.

[37]  B. Klein,et al.  Insulin‐like growth factor induces the survival and proliferation of myeloma cells through an interleukin‐6‐independent transduction pathway , 2000, British journal of haematology.

[38]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[39]  E. Sausville,et al.  Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. , 1999, Cancer research.

[40]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[41]  J. An,et al.  Critical Upstream Signals of Cytochrome c Release Induced by a Novel Bcl-2 Inhibitor* , 2004, Journal of Biological Chemistry.

[42]  B. Aggarwal,et al.  Flavopiridol Inhibits NF-κB Activation Induced by Various Carcinogens and Inflammatory Agents through Inhibition of IκBα Kinase and p65 Phosphorylation , 2004, Journal of Biological Chemistry.

[43]  V. Lauta,et al.  A review of the cytokine network in multiple myeloma , 2003, Cancer.

[44]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[45]  J. D. Vos,et al.  A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells , 2003, Oncogene.

[46]  S. Grant,et al.  Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents , 2004, Current oncology reports.

[47]  N. Munshi,et al.  Molecular sequelae of histone deacetylase inhibition in human malignant B cells. , 2003, Blood.

[48]  P. Dent,et al.  Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). , 2000, Biochemical pharmacology.

[49]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[50]  Clemencia Pinilla,et al.  Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. , 2004, Cancer cell.

[51]  Fei Chen,et al.  Reactive Oxygen Species (ROS), Troublemakers between Nuclear Factor-κB (NF-κB) and c-Jun NH2-terminal Kinase (JNK) , 2004, Cancer Research.

[52]  B. Blaylock,et al.  Clinical trials referral resource. Flavopiridol. , 2002, Oncology.

[53]  E. Sausville,et al.  Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. , 1998, Blood.

[54]  D. Bar-Sagi,et al.  Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. , 2000, Science.

[55]  H. Ichijo,et al.  Phosphorylation and Inactivation of Myeloid Cell Leukemia 1 by JNK in Response to Oxidative Stress* , 2002, The Journal of Biological Chemistry.

[56]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Lichtenstein,et al.  Interleukin-6 inhibits apoptosis of malignant plasma cells. , 1995, Cellular immunology.

[59]  S. Shangary,et al.  Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family , 2003, Leukemia.

[60]  S. Lewis,et al.  British Committee for Standards in Haematology , 1969 .

[61]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[62]  H. Yamaguchi,et al.  Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. , 2002, Cancer research.